ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer

The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer (BC). However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR inhibitor effectiveness. We developed ER+ BC cell lin...

Full description

Bibliographic Details
Main Authors: Elena Farmaki, Aritro Nath, Rena Emond, Kimya L Karimi, Vince K Grolmusz, Patrick A Cosgrove, Andrea H Bild
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2023-09-01
Series:eLife
Subjects:
breast cancer
drug resistance
everolimus
ONC201/TIC10
mitochondria
stress response
Online Access:https://elifesciences.org/articles/85898

Internet

https://elifesciences.org/articles/85898

Similar Items